E von Möllendorff

505 total citations
12 papers, 430 citations indexed

About

E von Möllendorff is a scholar working on Pediatrics, Perinatology and Child Health, Anesthesiology and Pain Medicine and Surgery. According to data from OpenAlex, E von Möllendorff has authored 12 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pediatrics, Perinatology and Child Health, 5 papers in Anesthesiology and Pain Medicine and 3 papers in Surgery. Recurrent topics in E von Möllendorff's work include Anesthesia and Sedative Agents (5 papers), Epilepsy research and treatment (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). E von Möllendorff is often cited by papers focused on Anesthesia and Sedative Agents (5 papers), Epilepsy research and treatment (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). E von Möllendorff collaborates with scholars based in United States and Germany. E von Möllendorff's co-authors include G. Neugebauer, K. Reiff, W. Akpan, Peter Neubert, B. Kaufmann, U. Abshagen, Ulrich Martin, R. Kientsch-Engel, G Betzien and G. Brunner and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Thrombosis and Haemostasis and European Journal of Clinical Pharmacology.

In The Last Decade

E von Möllendorff

12 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E von Möllendorff United States	9	168	88	72	61	59	12	430
W. Akpan United States	6	182 1.1×	81 0.9×	83 1.2×	54 0.9×	44 0.7×	9	384
K. Reiff United States	9	187 1.1×	98 1.1×	130 1.8×	50 0.8×	59 1.0×	16	515
P. Collste Sweden	16	141 0.8×	124 1.4×	104 1.4×	45 0.7×	46 0.8×	24	529
B. Kaufmann Germany	14	247 1.5×	68 0.8×	95 1.3×	86 1.4×	86 1.5×	29	650
Ola Rönn Sweden	13	172 1.0×	142 1.6×	83 1.2×	94 1.5×	60 1.0×	25	545
G. Bodem Germany	13	139 0.8×	74 0.8×	61 0.8×	42 0.7×	95 1.6×	47	463
H Wuttke Germany	8	230 1.4×	245 2.8×	63 0.9×	47 0.8×	78 1.3×	25	535
DA Willard United States	13	140 0.8×	91 1.0×	74 1.0×	160 2.6×	72 1.2×	18	592
L. Jordö Sweden	8	92 0.5×	101 1.1×	122 1.7×	32 0.5×	27 0.5×	15	333
David A Willard United States	11	190 1.1×	58 0.7×	33 0.5×	86 1.4×	176 3.0×	14	569

Countries citing papers authored by E von Möllendorff

Since Specialization

Citations

This map shows the geographic impact of E von Möllendorff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E von Möllendorff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E von Möllendorff more than expected).

Fields of papers citing papers by E von Möllendorff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E von Möllendorff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E von Möllendorff. The network helps show where E von Möllendorff may publish in the future.

Co-authorship network of co-authors of E von Möllendorff

This figure shows the co-authorship network connecting the top 25 collaborators of E von Möllendorff. A scholar is included among the top collaborators of E von Möllendorff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E von Möllendorff. E von Möllendorff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Martin, Ulrich, et al.. (1991). Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clinical Pharmacology & Therapeutics. 50(4). 429–436. 22 indexed citations

2.

Martin, Ulrich, E von Möllendorff, W. Akpan, et al.. (1991). Pharmacokinetic and Hemostatic Properties of the Recombinant Plasminogen Activator BM 06.022 in Healthy Volunteers. Thrombosis and Haemostasis. 66(5). 569–574. 45 indexed citations

3.

Brunner, G., et al.. (1988). Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver.. PubMed. 38(1A). 176–9. 18 indexed citations

4.

Möllendorff, E von, et al.. (1987). Pharmacokinetics and Disposition of Carvedilol in Humans. Journal of Cardiovascular Pharmacology. 10(Supplement). S85–S88. 20 indexed citations

5.

Neugebauer, G., W. Akpan, E von Möllendorff, Peter Neubert, & K. Reiff. (1987). Pharmacokinetics and Disposition of Carvedilol in Humans. Journal of Cardiovascular Pharmacology. 10. S85–S88. 71 indexed citations

6.

Möllendorff, E von, K. Reiff, & G. Neugebauer. (1987). Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. European Journal of Clinical Pharmacology. 33(5). 511–513. 70 indexed citations

7.

Neugebauer, G., W. Akpan, E von Möllendorff, Peter Neubert, & K. Reiff. (1987). Pharmacokinetics and Disposition of Carvedilol in Humans. Journal of Cardiovascular Pharmacology. 10. S85–S88. 1 indexed citations

8.

Neugebauer, G., W. Akpan, E von Möllendorff, Peter Neubert, & K. Reiff. (1987). Pharmacokinetics and disposition of carvedilol in humans.. PubMed. 10 Suppl 11. S85–8. 113 indexed citations

9.

Abshagen, U. & E von Möllendorff. (1986). Haemodynamic Abnormalities in Hypertensive Patients: A Review of the Influence of Vasodilating Drugs. Journal of International Medical Research. 14(6). 289–298. 2 indexed citations

10.

Möllendorff, E von, et al.. (1986). Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clinical Pharmacology & Therapeutics. 39(6). 677–682. 27 indexed citations

11.

Neugebauer, G., et al.. (1985). Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N).. PubMed. 23(9). 453–60. 36 indexed citations

12.

Möllendorff, E von, et al.. (1981). BM 12.434, a Novel Compound with Vasodilating and β-Adrenoceptor-Blocking Activities. Clinical Science. 61(s7). 477s–479s. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact